Wellcome Discovery Awards for MRCPPU Researchers
Published on 9 November 2022
Dr Greg Findlay and Professor Satpal Virdee, Principal Investigators in the MRC Protein Phosphorylation and Ubiquitylation Unit, have been awarded Wellcome Discovery Awards.
From left: Greg Findlay and Satpal Virdee
The 8-year funding that totals ~£4.2M will support their research in Intellectual Disability and E3 ligase enzymes, respectively.
This new scheme from the Wellcome Trust ‘provides funding for established researchers and teams from any discipline who want to pursue bold and creative research ideas to deliver significant shifts in understanding that could improve human life, health and wellbeing’.
“Intellectual disability is a major mental health problem that affects 1-3% of the world population, which is frequently caused by genetic mutations that disrupt cell communication. In our research programme, we will develop and deploy cutting-edge biochemical approaches in stem cell models of human nervous system development, to understand how defective cell communication causes intellectual disability. This will identify new therapeutic targets, which we hope will eventually lead to treatments for these debilitating conditions,” explained Greg. “This research stems from previous work published by our group in Cell Reports, Developmental Cell and Science Signalling.”
Greg was awarded ~£1.9M which will support 3 full-time positions. He will collaborate with researchers from the University of Dundee, University of Glasgow, MRC Mary Lyon Centre at Harwell, Oxford and University of Exeter.
“E3 ligase enzymes regulate virtually all aspects of the cell and their overactivity, or lack thereof, underlies diseases including cancer, neurodegeneration and autoimmunity. E3 enzymes are also central to a promising new class of medicines known as degraders. This Wellcome Discovery will uncover and characterize novel members of this important enzyme family with a view to unlocking new fundamental biology and strategies for treating disease. Technology will also be developed that will facilitate the study of E3 enzymes and the development of medicines that modulate their activity,” explained Satpal. “This work will build upon previous research published by us in Nature Chemical Biology, Cell Chemical Biology and Nature”.
Satpal was awarded ~£2.3M which will support 4 full-time positions and will collaborate with researchers from Institute of Molecular Pathology (Austria).
Dario Alessi, Director of the MRC-PPU